Relmada Therapeutics, Inc.
RLMD
$6.27
$0.559.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.05M | -19.87M | -10.09M | -9.87M | -17.56M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.18M | 4.25M | 3.59M | 3.44M | 4.26M |
| Change in Net Operating Assets | -199.30K | 1.02M | -221.40K | 24.90K | -4.77M |
| Cash from Operations | -15.07M | -14.60M | -6.72M | -6.40M | -18.07M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -135.23M | -76.93M | 6.75M | 6.68M | 15.36M |
| Cash from Investing | -135.23M | -76.93M | 6.75M | 6.68M | 15.36M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 160.00M | 93.64M | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.43M | 0.00 | 0.00 | -73.00K | -- |
| Cash from Financing | 156.57M | 93.64M | 0.00 | -73.00K | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.28M | 2.11M | 31.10K | 203.60K | -2.71M |